Posted by Michael Wonder on 03 May 2023
US FDA grants breakthrough therapy designation for spesolimab for the prevention of flares in adults with generalised pustular psoriasis
2 May 2023 - Breakthrough therapy designation is supported by results from the Effisayil 2 trial which studied spesolimab in the prevention of flares in adults with generalised pustular psoriasis.
Boehringer Ingelheim today announced that the US FDA granted breakthrough therapy designation for spesolimab as an investigational treatment for the prevention of flares in adults with generalised pustular psoriasis.
